Japan’s largest drugmaker Takeda (TYO: 4502) decided to discontinue the development programs of its four oncology assets - Phase III asset modakafusp alfa (TAK-573) and three Phase I chimeric antigen receptor (CAR-T) assets: TAK-102, TAK-103 and TAK-940 - as part of a plan to align its focus on advancing allogeneic cell therapies.
Despite these adjustments, the Japan-based pharma major's oncology pipeline remains robust, says pharma analytics company GlobalData.
Takeda entered into multiple cell therapy collaborations for the development of CAR-T therapies with organizations like Memorial Sloan Kettering Cancer Center (MSK), Noile-Immune Biotech, and Crescendo Biologics in 2019 to advance the company’s novel immuno-oncology portfolio. Subsequently, the company had established a cell therapy manufacturing facility in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze